Alloplex Biotherapeutics

Information for patients and carers on SUPLEXA, Alloplex's autologous cell therapy, and clinical trial participation for metastatic solid tumors.

Immuno-Oncology Insights Magazine 2023; 4(3), 89–104 DOI: 10.18609/ioi.2022.013 Alloplex Commentary: SUPLEXA immunotherapeutic cells show promise in

Achieving durable responses in advanced oncology remains the most critical challenge for innate cell therapies. As the industry seeks to move beyond the

An Interview with Frank Borriello, CEO, Alloplex Biotherapeutics about advances in immuno-oncology and current challenges that need immediate attention. This

Every era of science eventually outgrows the systems built to steer it. In cellular and genetic therapeutics, that moment has arrived. As Dr. Arnold Coller

Dr. Frank Borriello discusses the effects of U.S. federal funding cuts on scientific research, the value of NIH investments, and potential consequences of losing a generation of researchers.

Targeted Oncology reported that the FDA granted Fast Track designation to suplexa, a non-engineered autologous cellular immunotherapy.

The latest about Alloplex.

SITC 2023 Poster 381 and 727 with Audio Commentary by Dr. Borriello

Designation recognizes the potential of SUPLEXA therapeutic cells in addressing high unmet need in patients with solid tumors

Dr. Borriello speaks of collective responsibility amongst all involved in developing drugs to combat cancer.

Alloplex Biotherapeutics seeks strategic partners for its non-engineered immune cell training approach to cancer.

The company developed a non-engineered autologous PBMC-derived cellular therapy to treat cancer, based on the observation that activating known immune pathways can elicit anti-tumor activity.

Sharron Gargosky, PhD, is a consultant to Alloplex Biotherapeutics, supporting development of the SUPLEXA autologous cellular immunotherapy for cancer.

Steve Schiffman is a member of the Corporate Advisory Panel at Alloplex Biotherapeutics, the developer of the SUPLEXA autologous cellular therapy.

Alloplex Biotherapeutics Inc is a privately owned Boston-based cellular therapeutics. Its headquarters and laboratories are located in Woburn MA, USA

Please fill in the form below.

Explore SUPLEXA FAQs: autologous, non-engineered cell therapy, completed Phase 1 solid-tumour data, FDA Fast Track in MSI-high CRC, IP and development plans.

Alloplex presents a patented cell-retraining platform that, by utilizing synergy between key immune pathways, reveals a previously unappreciated dimension of human immunology.

The company lists its website address as https://alloplexbio.com.

The page sets out terms governing use of the website and states that continued use constitutes agreement to them.